Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples